Timothy E. Adams
YOU?
Author Swipe
View article: The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice
The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice Open
The chimeric cytokine IC7Fc conveys the metabolic signaling properties of the glycoprotein 130 receptor cytokines interleukin-6 and ciliary neurotrophic factor via membrane-bound signaling. IC7Fc was previously shown to slow the progressio…
View article: EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR
EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR Open
The epidermal growth factor receptor (EGFR) is aberrantly activated in many human epithelial cancers. This report presents the preparation, purification, and the anti-cancer potency of an anti-EGFR affibody (Z EGFR 1907’ )-polyethylenimine…
View article: Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice
Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice Open
Exercise training is anti-tumorigenic in a mouse model of luminal breast cancer, but the effect is abrogated by social isolation. The proteoglycan decorin is an exercise-induced secretory protein, and tumor decorin levels are positively as…
View article: Development and preliminary validation of a MERS-CoV ELISA for serological testing of camels and alpacas
Development and preliminary validation of a MERS-CoV ELISA for serological testing of camels and alpacas Open
This study describes the development and preliminary validation of a new serological assay using MERS-CoV S1 protein in an indirect enzyme-linked immunosorbent assay (ELISA) format. This assay has the advantage of being able to test MERS-C…
View article: Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer
Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer Open
Despite the clinical benefits that chemotherapeutics has had on the treatment of breast cancer, drug resistance remains one of the main obstacles to curative cancer therapy. Nanomedicines allow therapeutics to be more targeted and effectiv…
View article: Supplementary Figure 7 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 7 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Dose escalation study of chDAB4-SG3249 alone or in combination with chemotherapy in LL2 tumor model.
View article: Supplementary Figure 3 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 3 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Chemotherapy increases cathepsin B expression and macrophages in tumors.
View article: Supplementary Figure 2 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 2 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
chDAB4 binds within the apoptotic/necrotic regions of lung tumor xenografts.
View article: Supplementary Figure 3 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 3 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Chemotherapy increases cathepsin B expression and macrophages in tumors.
View article: Data from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Data from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Antibody–drug conjugates (ADC) have revolutionized the field of cancer therapy. ADCs combine the high specificity of tumor-targeting monoclonal antibodies with potent cytotoxic drugs, which cannot be used alone because of their high toxici…
View article: Supplementary Figure 2 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 2 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
chDAB4 binds within the apoptotic/necrotic regions of lung tumor xenografts.
View article: Supplementary Figure 4 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 4 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Dose escalation study of DAB4-MMAE and DAB4-Duocarmycin DM alone or in combination with chemotherapy in LL2 tumor model.
View article: Supplementary Figure 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Chemical structure of MC-PEG4-VC-PAB-Duocarmycin DM, and chDAB4 binding and phagocytosis of dead tumour cells treated with ADC drugs.
View article: Supplementary Table 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Table 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Antibody drug conjugates used in the study.
View article: Supplementary Figure 7 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 7 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Dose escalation study of chDAB4-SG3249 alone or in combination with chemotherapy in LL2 tumor model.
View article: Data from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Data from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Antibody–drug conjugates (ADC) have revolutionized the field of cancer therapy. ADCs combine the high specificity of tumor-targeting monoclonal antibodies with potent cytotoxic drugs, which cannot be used alone because of their high toxici…
View article: Supplementary Figure 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Chemical structure of MC-PEG4-VC-PAB-Duocarmycin DM, and chDAB4 binding and phagocytosis of dead tumour cells treated with ADC drugs.
View article: Supplementary Table 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Table 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Antibody drug conjugates used in the study.
View article: Supplementary Figure 6 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 6 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
DAB4-ADCs with cleavable, but not non-cleavable linkers, are effective in vivo.
View article: Supplementary Figure 6 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 6 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
DAB4-ADCs with cleavable, but not non-cleavable linkers, are effective in vivo.
View article: Supplementary Figure 5 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 5 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Survival curves for mice treated with DAB4 or chDAB4 antibody drug conjugates.
View article: Supplementary Figure 5 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 5 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Survival curves for mice treated with DAB4 or chDAB4 antibody drug conjugates.
View article: Supplementary Figure 4 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i>
Supplementary Figure 4 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective <i>In Vivo</i> Open
Dose escalation study of DAB4-MMAE and DAB4-Duocarmycin DM alone or in combination with chemotherapy in LL2 tumor model.
View article: Data from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i>
Data from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i> Open
Elevated expression of insulin-like growth factor-II (IGF-II) is frequently observed in a variety of human malignancies, including breast, colon, and liver cancer. As IGF-II can deliver a mitogenic signal through both IGF-IR and an alterna…
View article: Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i>
Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo
View article: Data from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i>
Data from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i> Open
Elevated expression of insulin-like growth factor-II (IGF-II) is frequently observed in a variety of human malignancies, including breast, colon, and liver cancer. As IGF-II can deliver a mitogenic signal through both IGF-IR and an alterna…
View article: Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i>
Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines <i>In vitro</i> and <i>In vivo</i> Open
Supplementary Table from A Human Monoclonal Antibody against Insulin-Like Growth Factor-II Blocks the Growth of Human Hepatocellular Carcinoma Cell Lines In vitro and In vivo
View article: A practical method for estimating climate-related changes to riverine flood elevation and frequency
A practical method for estimating climate-related changes to riverine flood elevation and frequency Open
Floods have been occurring with increasing frequency, leading to damage to communities worldwide. These impacts are expected to continue to rise due to increases in the intensity of extreme rainfall. Global climate model (GCM) output, whil…